These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 23758591)
21. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Chen KT; Lee TW; Lo JM Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002 [TBL] [Abstract][Full Text] [Related]
22. Facile preparation of cationic gold nanoparticle-bioconjugates for cell penetration and nuclear targeting. Ojea-Jiménez I; García-Fernández L; Lorenzo J; Puntes VF ACS Nano; 2012 Sep; 6(9):7692-702. PubMed ID: 22870984 [TBL] [Abstract][Full Text] [Related]
23. Smart nanoprobes for ultrasensitive detection of breast cancer via magnetic resonance imaging. Lee J; Yang J; Seo SB; Ko HJ; Suh JS; Huh YM; Haam S Nanotechnology; 2008 Dec; 19(48):485101. PubMed ID: 21836291 [TBL] [Abstract][Full Text] [Related]
24. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319 [TBL] [Abstract][Full Text] [Related]
25. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Miyano T; Wijagkanalan W; Kawakami S; Yamashita F; Hashida M Mol Pharm; 2010 Aug; 7(4):1318-27. PubMed ID: 20527783 [TBL] [Abstract][Full Text] [Related]
26. SERS imaging of HER2-overexpressed MCF7 cells using antibody-conjugated gold nanorods. Park H; Lee S; Chen L; Lee EK; Shin SY; Lee YH; Son SW; Oh CH; Song JM; Kang SH; Choo J Phys Chem Chem Phys; 2009 Sep; 11(34):7444-9. PubMed ID: 19690717 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A; Colomer R; Brunet J; Menendez JA Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307 [TBL] [Abstract][Full Text] [Related]
28. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Nielsen UB; Adams GP; Weiner LM; Marks JD Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810 [TBL] [Abstract][Full Text] [Related]
29. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Cruz LJ; Tacken PJ; Fokkink R; Figdor CG Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247 [TBL] [Abstract][Full Text] [Related]
30. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546 [TBL] [Abstract][Full Text] [Related]